Torrent Pharmaceuticals Limited , one of India's leading pharmaceutical companies, has announced robust financial results for the first quarter of fiscal year 2026, demonstrating strong growth across its key markets.

Financial Highlights

Market Performance

India

• India revenues rose by 11% to Rs. 1,811.00 crores, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%
• Chronic business grew by 13%, compared to the IPM growth of 9% in this segment
• The company now has 21 brands in the Top 500 IPM brands, with 14 brands generating over Rs. 100.00 crores in sales

Brazil

• Brazil revenues increased by 11% to Rs. 218.00 crores
• In constant currency terms, revenues grew by 16% to R$ 143.00 million
• Torrent Pharmaceuticals outperformed the market with 14% growth compared to overall market growth of 5%
• Growth was driven by strong performance of top brands and new product launches
• The company has 62 products under review by ANVISA, Brazil's health regulatory agency

Germany

• Germany revenues grew by 9% to Rs. 308.00 crores
• Constant currency revenues increased by 1% to EUR 32.00 million
• Growth was impacted by supply disruptions from a third-party manufacturer

United States

• US business revenues surged by 19% to Rs. 308.00 crores
• Constant currency revenues grew by 16% to $36.00 million
• Recent product launches have achieved their targeted market shares

R&D and Future Outlook

Torrent Pharmaceuticals continues to invest in research and development, with R&D spend increasing by 16% to Rs. 157.00 crores, representing 5% of total revenues. This investment underscores the company's commitment to innovation and future growth.

Management Commentary

Samir Mehta, Executive Chairman of Torrent Pharmaceuticals Limited, commented on the results, stating, "We are pleased with our strong start to FY26, with robust growth across our key markets. Our focus on chronic therapies and strategic launches has paid off, particularly in India and Brazil. While we face some challenges in Germany due to supply disruptions, we are working to address these issues. Our U.S. business continues to show promising growth, and we remain committed to expanding our presence in this important market."

Conclusion

Torrent Pharmaceuticals' Q1 FY26 results demonstrate the company's resilience and strong market position. With a diverse geographical presence, focus on chronic therapies, and continued investment in R&D, Torrent Pharmaceuticals is well-positioned for sustained growth in the coming quarters.

Torrent Pharmaceuticals Limited , a leading Indian pharmaceutical company, has announced robust financial results for the first quarter, showcasing significant growth across key markets and financial metrics.

Financial Highlights

• Revenue reached Rs. 3,178.00 crores, marking an 11% year-on-year growth
• Operating EBITDA increased by 14% to Rs. 1,032.00 crores
• Net profit after tax surged by 20% to Rs. 548.00 crores
• Gross margin remained steady at 76%
• Operating EBITDA margin stood at 32.5%

Market Performance

India

• India revenues grew by 11% to Rs. 1,811.00 crores
• Chronic business outperformed with 13% growth compared to 9% IPM growth
• 21 brands featured in the Top 500 brands of Indian Pharmaceutical Market (IPM)
• 14 brands achieved sales exceeding Rs. 100.00 crores

Brazil

• Brazil revenues increased by 11% to Rs. 218.00 crores
• Constant currency revenues rose by 16% to R$ 143.00 million
• Torrent's growth rate of 14% outpaced the market growth of 5%
• 62 products currently under ANVISA review

Germany

• Germany revenues grew by 9% to Rs. 308.00 crores
• Constant currency revenues increased by 1% to EUR 32.00 million
• Growth was impacted by supply disruptions from a third-party supplier

United States

• US business revenues surged by 19% to Rs. 308.00 crores
• Constant currency revenues increased by 16% to $36.00 million
• Recent product launches achieved targeted market shares

R&D Investment

Torrent Pharmaceuticals continued its focus on research and development:

• R&D spend increased by 16% to Rs. 157.00 crores
• R&D expenditure accounted for 5% of total revenues

Company Overview

Torrent Pharmaceuticals Limited, the flagship company of the Torrent Group, reported annual revenues exceeding Rs. 11,500.00 crores. The company maintains a strong position in the Indian pharmaceutical market:

• Ranked 7th overall in the Indian Pharmaceuticals Market
• Among the Top 5 in key therapeutic segments: Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), and Cosmo-Dermatology
• Specialty-focused with approximately 76% of India revenues from chronic and sub-chronic therapies
• Present in over 50 countries
• Ranked 1st among Indian pharma companies in Brazil and Germany
• Operates 8 manufacturing facilities, including 5 USFDA-approved sites
• Employs over 750 scientists in state-of-the-art R&D infrastructure

Torrent Pharmaceuticals' strong Q1 performance underscores its successful strategy of focusing on chronic therapies and expanding its presence in key international markets. The company's continued investment in R&D and its robust pipeline of products under review suggest a positive outlook for future growth and innovation in the pharmaceutical sector.